Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Sep 14, 2016

Keywords

ClinConnect Summary

The Ontario-wide Cancer Targeted Nucleic Acid Evaluation trial is studying how to better understand and treat various types of cancer, including breast, lung, and colorectal cancers, among others. The goal is to collect and analyze tumor samples from patients who have advanced cancer to identify specific characteristics, known as biomarkers, that can help doctors determine the most effective treatments for each individual. This information could also assist in finding suitable clinical trials for new drugs that may work better for certain patients.

To participate in this study, patients must be at least 18 years old and have a confirmed diagnosis of advanced solid tumors that require treatment. They should also have enough previously collected tumor tissue available for testing. Once enrolled, participants can expect their tumor and blood samples to be stored for future research and to have their health data linked to other medical records to enhance understanding of cancer treatment outcomes. This study aims to create a valuable resource for cancer research and potentially improve treatment options for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.
• • 2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.
• • 3. Patient must be ≥ 18 years old.
• • 4. Patient's ECOG performance status equal to 0 or 1.
• • 5. All patients must have a life expectancy of \> 6 months.
• • 6. All patients must have adequate organ functions.
• • 7. All patients must have signed and dated an informed consent form.
• Exclusion Criteria:
• • 1. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.